GSK supports the launch of "Happy Breath", COPD Tiered Diagnosis and Treatment Project across China

Supported by GSK, "Happy Breath", COPD Tiered Diagnosis and Treatment Project (“the project”) was launched in Beijing today. The project is organised by the Chinese Association for Health Promotion and Education, the Respiratory Subspecialty Cluster of China-Japan Friendship Hospital and the Telemedicine Management Training Centre of National Health and Family Planning Commission, and co-organised by the Chinese Association of Chest Physicians. Tapping on the benefits of Subspecialty Cluster and telemedicine, it is designed to better promote and implement COPD tiered diagnosis and treatment, and improve grassroots health capabilities. 

The project is expected to last for three years, benefiting around 18 million Chinese citizens. The first 12 months will cover all the hospitals and healthcare clinics in the eight selected pilot cities/areas. It aims to enhance grassroots health capabilities through online and offline trainings, telemedicine and tele-discussion on difficult cases, the suitable use of guideline recommended COPD treatment and spirometry test. It will also encourage the two-way referral and synergy between pulmonary specialists and general practitioners for an enhanced tiered-healthcare system and better COPD disease management. The objective of disease education is to raise public awareness on COPD and encourage early screening and appropriate treatment for a better health outcome. 

Professor Chen Wang, Academician of Chinese Academy of Engineering and President of China-Japan Friendship Hospital said: "COPD is one of the most common chronic respiratory diseases. Characterised by high prevalence, disability, mortality and disease burden, it becomes a serious public health issue. The project will explore ways to implement tiered diagnosis and treatment for COPD by setting up key pilot areas to standardise the process and enhance disease management for COPD among physicians at all levels. It will also help to increase patients' awareness of COPD and encourage their self-management, so as to enhance patients’ quality of life and reduce the social burden of COPD."

According to the Report on nutrition and chronic diseases in Chinese residents (2015), the prevalence of COPD among people aged 40 and above in China is 9.9%1. WHO data shows that China ranks the first in the world in terms of COPD mortality, with 79.4 per 100 thousand2 in 2013; China statistical yearbook 2016 shows that respiratory disease is the fourth  leading cause of death among Chinese residents, following malignant tumours, heart disease and cerebrovascular disease in 2015.3

Dr. Wim Swyzen, VP and Country Medical Director for GSK China said: "COPD is frequently underdiagnosed and undertreated. GSK has extensive experience in the research and development of respiratory medicine globally, including COPD. By supporting the project, we hope to raise the awareness of COPD among primary care physicians and patients; help patients better manage disease, prevent exacerbation, slow down disease progression and improve their quality of life through early screening, timely diagnosis, and standardised medication, etc."

Since 2015, GSK has cooperated with the National Health and Family Planning Commission to conduct a COPD training program for around 4,000 primary physicians so far. In June this year, GSK signed a memorandum to form a strategic cooperation with the Guangzhou Institute of Respiratory Disease to build a big data system for health and enhance the overall respiratory disease management system in China.


As part of the ‘in China, with China, for China’ strategy, GSK China has:

  • Announced Flixotide Nebules received approval for the treatment of children asthma in September 2017.
  • Announced partnership with Ali Health to launch innovative online service platform to improve adult vaccination consultation experience in Aug 2017.
  • Announced innovative antiretroviral Single Tablet Regimen Triumeq received approval in China in Aug 2017.
  • Announced Cervarix, first vaccine for cervical cancer prevention in mainland China, was officially launched in July 2017.
  • Announced the collaboration programme to aid hepatitis prevention and treatment in poverty-stricken areas of the western region in July 2017.
  • Announced Seroxat CR and Tykerb on the list of reimbursed drugs as results of the national health insurance negotiations in July 2017.
  • Announced a strategic partnership with academia to co-develop health big-data system and upgrade the management of respiratory diseases in June 2017.
  • Aided the National Preventive Vaccination Services and Management Training Programme, helmed by the Chinese Preventive Medicine Association under the guidance of the National Health and Family Planning Commission, with the support of the China Centre for Disease Control and Prevention that officially kicked off in June 2017.
  • Announced Viread, Arixtra, Requip and Mivacron included in the “2017 National Reimbursement Drug List” in Mar 2017.
  • Joined hands with the Home of Red Ribbon to combat HIV/AIDS, unveiling plan to support people living with HIV in Nov 2016.
  • Announced the strategic partnership with China Preventive Medicine Association (CPMA) to address major public health challenges in China in Nov 2016.
  • Announced the approval of Cervarix in China to help protect women from cervical cancer in July 2016.
  • Announced a Memorandum of Understanding between the GSK Institute for Infectious Diseases and Public Health and Tsinghua University to tackle global public health challenges in June 2016.
  • Launched Tivicay, an innovative HIV drug, in June 2016.
  • Participated in the national price negotiation pilot and announced a price reduction of our first line chronic hepatitis B treatment, Viread, by up to 67% in May 2016.
  • Announced a Beijing-based Institute for Infectious Disease and Public Health to conduct local development programmes for pivotal HIV and TB R&D assets in March 2016.
  • Partnered with the National Health and Family Planning Commission on a multi-year programme to fund independent training programmes in Hepatitis and COPD for over 13,000 healthcare professionals from September 2015.
  • Transformed our commercial operating model to actively contribute to improving the quality of scientific exchanges with healthcare professionals for the benefit of patients since May 2015.


GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit


GSK commitment to China

We are a science-led global healthcare company. We research, develop and manufacture a wide range of medicines, vaccines and consumer healthcare products. People are at the heart of what we do. We strive to bring high quality, high performing products to everyone who needs them. Creating innovative products and improving access to them is critical to our mission, allowing us to help build stronger, healthier communities. In China, and around the world, we are on a mission to help people do more, feel better, live longer. We are in China, with China, for China, and our commitment remains unwavering.


GSK enquiries:

Susan Song            (China)




1.Report on nutrition and chronic diseases in Chinese residents (2015)

2. Yin P, et al. Chest. 2016 Dec;150(6):1269-1280

3. China statistical yearbook 2016


Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2016.